Novartis Ag

Miltenyi Biotec B.v. Co., Kg

Nina Moker

Bijan Etemad-Gilbertson

Joy Gispati Ghosh

Nicole Haubst

Michael Stefanidakis

Chad Eric Bigelow

Wing Leung

Volker Huppert

Engin Toksoz

Stephen Hedrick Poor

Rafijul Bari

Markus Granzin

Andrew Anh Nguyen

Yubin Qiu

Nalini Velamur Rangaswamy

Michael Zbigniew Twarog

Ana Maria Carrion

James Edgar Chastain

Kirk Lee Clark

Shawn Michael Hanks

Ganesh Rajan Iyer

The present invention discloses an in-vitro method for transferring biological material into activated NK cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, comprising the steps a) activation of NK cells, and b) addition of said pseudotyped retroviral vector particle or virus-like particle thereof to said activated NK cells, wherein said pseudotyped retroviral vector particle or virus-like particle thereof comprises a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein that is able of binding to and fusing with a hematopoietic cell membrane, thereby transferring biological material into said activated NK cells. Preferentially, the activating of NK cells is performed by the addition of a IL-1 family cytokine to the NK cells.

Method for NK cell transduction

The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.

Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules

Growing community of inventors

Cologne, Germany

Nina Moker